دورية أكاديمية
أعرض في EDS

Anti-CEA loaded maghemite nanoparticles as a theragnostic device for colorectal cancer.

التفاصيل البيبلوغرافية
العنوان: Anti-CEA loaded maghemite nanoparticles as a theragnostic device for colorectal cancer.
المؤلفون: da Paz MC; Instituto de Ciências Biológicas, Universidade de Brasília, Brasília, DF, Brazil., Santos Mde F, Santos CM, da Silva SW, de Souza LB, Lima EC, Silva RC, Lucci CM, Morais PC, Azevedo RB, Lacava ZG
المصدر: International journal of nanomedicine [Int J Nanomedicine] 2012; Vol. 7, pp. 5271-82. Date of Electronic Publication: 2012 Oct 04.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: DOVE Medical Press Country of Publication: New Zealand NLM ID: 101263847 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1178-2013 (Electronic) Linking ISSN: 11769114 NLM ISO Abbreviation: Int J Nanomedicine Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Auckland : DOVE Medical Press,
مواضيع طبية MeSH: Antibodies, Monoclonal/*therapeutic use , Carcinoembryonic Antigen/*immunology , Colorectal Neoplasms/*drug therapy , Colorectal Neoplasms/*pathology , Magnetite Nanoparticles/*chemistry , Magnetite Nanoparticles/*therapeutic use, Antibodies, Monoclonal/immunology ; Cell Line, Tumor ; Ferric Compounds/chemistry ; Humans ; Nanocapsules/therapeutic use
مستخلص: Nanosized maghemite particles were synthesized, precoated (with dimercaptosuccinic acid) and surface-functionalized with anticarcinoembryonic antigen (anti-CEA) and successfully used to target cell lines expressing the CEA, characteristic of colorectal cancer (CRC) cells. The as-developed nanosized material device, consisting of surface decorated maghemite nanoparticles suspended as a biocompatible magnetic fluid (MF) sample, labeled MF-anti-CEA, was characterized and tested against two cell lines: a high-CEA expressing cell line (LS174T) and a low-CEA expressing cell line (HCT116). Whereas X-ray diffraction was used to assess the average core size of the as-synthesized maghemite particles (average 8.3 nm in diameter), dynamic light scattering and electrophoretic mobility measurements were used to obtain the average hydrodynamic diameter (550 nm) and the zeta-potential (-38 mV) of the as-prepared and maghemite-based nanosized device, respectively. Additionally, surface-enhanced Raman spectroscopy (SERS) was used to track the surface decoration of the nanosized maghemite particles from the very first precoating up to the attachment of the anti-CEA moiety. The Raman peak at 1655 cm(-1), absent in the free anti-CEA spectrum, is the signature of the anti-CEA binding onto the precoated magnetic nanoparticles. Whereas MTT assay was used to confirm the low cell toxicity of the MF-anti-CEA device, ELISA and Prussian blue iron staining tests performed with both cell lines (LS174T and HCT116) confirm that the as-prepared MF-anti- CEA is highly specific for CEA-expressing cells. Finally, transmission electron microscopy analyses show that the association with anti-CEA seems to increase the number of LS174T cells with internalized maghemite nanoparticles, whereas no such increase seems to occur in the HCT116 cell line. In conclusion, the MF-anti-CEA sample is a biocompatible device that can specifically target CEA, suggesting its potential use as a theragnostic tool for CEA-expressing tumors, micrometastasis, and cancer-circulating cells.
References: Nanoscale. 2011 Feb;3(2):387-90. (PMID: 20877896)
J Magn Reson Imaging. 2011 Jan;33(1):194-202. (PMID: 21182139)
J Nanobiotechnology. 2011 Mar 28;9:11. (PMID: 21443799)
Nanomedicine (Lond). 2011 Nov;6(9):1529-44. (PMID: 21675858)
Oncol Rep. 2012 Apr;27(4):947-53. (PMID: 22267181)
J Nanopart Res. 2011 Oct 1;13(10):4717-4729. (PMID: 22121333)
Analyst. 2011 Aug 7;136(15):3083-90. (PMID: 21666913)
Scand J Immunol. 2003 Dec;58(6):628-41. (PMID: 14636419)
Biomaterials. 2010 Jan;31(2):366-74. (PMID: 19822361)
Nanotechnology. 2011 Dec 16;22(50):505103. (PMID: 22107797)
J Nanosci Nanotechnol. 2008 Nov;8(11):5873-7. (PMID: 19198320)
J Gastrointest Surg. 2010 Feb;14 Suppl 1:S2-5. (PMID: 19768512)
Biomaterials. 2011 Dec;32(35):9155-8. (PMID: 21963282)
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. (PMID: 21685461)
ACS Appl Mater Interfaces. 2011 Oct;3(10):4085-91. (PMID: 21882840)
Theranostics. 2012;2(1):76-85. (PMID: 22272221)
Chem Res Toxicol. 2010 Dec 20;23(12):1874-82. (PMID: 21067130)
Langenbecks Arch Surg. 2010 Aug;395(6):633-41. (PMID: 20213463)
J Am Chem Soc. 2011 Aug 17;133(32):12624-31. (PMID: 21744804)
Acad Radiol. 2011 Apr;18(4):504-11. (PMID: 21216633)
J Cell Physiol. 1999 Feb;178(2):173-8. (PMID: 10048581)
J Biomol Screen. 2011 Oct;16(9):1018-26. (PMID: 21807963)
Cancer. 2010 Feb 15;116(4 Suppl):1111-7. (PMID: 20127959)
Anal Chem. 2009 Nov 15;81(22):9425-32. (PMID: 19803497)
Analyst. 2010 Dec;135(12):3038-41. (PMID: 20949209)
Biomaterials. 2009 Oct;30(29):5737-50. (PMID: 19631377)
Acad Radiol. 2010 Dec;17(12):1468-76. (PMID: 20869887)
Nanotechnology. 2010 Feb 19;21(7):75102. (PMID: 20090199)
Hepatogastroenterology. 2011 Mar-Apr;58(106):347-51. (PMID: 21661394)
BMC Cancer. 2010 Mar 30;10:119. (PMID: 20350328)
Nat Nanotechnol. 2009 Dec;4(12):855-60. (PMID: 19915570)
Pharm Res. 2012 May;29(5):1180-8. (PMID: 22274558)
Cancer. 2012 Feb 1;118(3):639-50. (PMID: 21853445)
Pharmacol Ther. 2010 Nov;128(2):324-35. (PMID: 20705093)
Int J Nanomedicine. 2011;6:1709-17. (PMID: 21980234)
Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2153-64. (PMID: 21858527)
Biomaterials. 2011 Oct;32(29):7139-50. (PMID: 21726899)
Biomaterials. 2012 Mar;33(7):2215-22. (PMID: 22169825)
Dis Colon Rectum. 2007 Nov;50(11):1887-98. (PMID: 17882488)
J Phys Chem A. 2011 Feb 17;115(6):1003-8. (PMID: 21261312)
فهرسة مساهمة: Keywords: Raman; anti-CEA antibody; biocompatible device; diagnostic; magnetic nanoparticles; targeted delivery
المشرفين على المادة: 0 (Antibodies, Monoclonal)
0 (Carcinoembryonic Antigen)
0 (Ferric Compounds)
0 (Magnetite Nanoparticles)
0 (Nanocapsules)
1K09F3G675 (ferric oxide)
تواريخ الأحداث: Date Created: 20121012 Date Completed: 20130117 Latest Revision: 20211021
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC3468277
DOI: 10.2147/IJN.S32139
PMID: 23055733
قاعدة البيانات: MEDLINE
الوصف
تدمد:1178-2013
DOI:10.2147/IJN.S32139